Published in J Virol on July 01, 1991
Foot-and-mouth disease. Clin Microbiol Rev (2004) 4.34
Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies. J Virol (1991) 1.89
Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol (1992) 1.72
Oligo(A) sequences of human respiratory syncytial virus G protein gene: assessment of their genetic stability in frameshift mutants. J Virol (1994) 0.96
A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res (1984) 181.98
The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature (1989) 5.87
Nucleotide sequence heterogeneity of an RNA phage population. Cell (1978) 5.55
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene (1985) 3.42
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene (1976) 2.77
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene (1980) 2.44
RNA virus quasispecies populations can suppress vastly superior mutant progeny. J Virol (1990) 2.12
Immunochemical studies of foot-and-mouth disease. VII. Characterization of foot-and-mouth disease virus concentrated by polyethylene glycol precipitation. Arch Gesamte Virusforsch (1970) 1.93
Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J Virol (1988) 1.92
Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J Virol (1988) 1.90
Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology (1985) 1.84
Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71
The effect of peptides containing the arginine-glycine-aspartic acid sequence on the adsorption of foot-and-mouth disease virus to tissue culture cells. Virus Genes (1990) 1.70
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol (1987) 1.53
Fixation of mutations in the viral genome during an outbreak of foot-and-mouth disease: heterogeneity and rate variations. Gene (1986) 1.53
Antigenic sites on foot-and-mouth disease virus type A10. J Virol (1988) 1.48
Early interactions of foot-and-mouth disease virus with cultured cells. Virology (1980) 1.45
Translation of foot-and-mouth disease virion RNA and processing of the primary cleavage products in a rabbit reticulocyte lysate. Virology (1982) 1.44
Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol (1989) 1.17
Antigenic variation of foot-and-mouth disease virus of serotype C during propagation in the field is mainly restricted to only one structural protein (VP1). Virus Res (1989) 1.16
Selection of antigenic variants of foot-and-mouth disease virus in the absence of antibodies, as revealed by an in situ assay. J Gen Virol (1989) 1.15
Genetic and immunogenic variations among closely related isolates of foot-and-mouth disease virus. Gene (1988) 1.12
A continuous bovine kidney cell line for routine assays of foot-and-mouth disease virus. Vet Microbiol (1988) 1.09
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies. J Gen Virol (1989) 1.01
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies. J Gen Virol (1986) 0.97
Genetic and phenotypic variability during replication of foot-and-mouth disease virus in swine. Virology (1990) 0.96
Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res (1989) 0.90
Modeling and computer stimulation approach to the mechanism of foot-and-mouth disease virus neutralization assays. Scand J Immunol (1977) 0.85
STUDIES ON PNEUMONIA IN CHILDREN: I. Mortality, Blood Cultures, and Humoral Antibodies in Pneumococcus Pneumonia. J Clin Invest (1930) 11.23
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J Virol (1996) 2.77
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. J Virol (1985) 2.65
Changing the needle when inoculating blood cultures. A no-benefit and high-risk procedure. JAMA (1990) 2.04
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol (1987) 1.77
Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol (1975) 1.76
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Synthesis of endogenous pyrogen by rabbit leukocytes. J Exp Med (1973) 1.58
Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase. Virology (1983) 1.51
Studies on the pathogenesis of fever. 18. Activation of leukocytes for pyrogen production. J Exp Med (1970) 1.49
Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol (1984) 1.46
Changes in total light scattering and absorption caused by changes in particle conformation. J Theor Biol (1968) 1.40
Office-based system for voice analysis. Arch Otolaryngol Head Neck Surg (1989) 1.39
Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology (1979) 1.26
Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest (1996) 1.21
Synthesis of four endogenous pyrogens by rabbit macrophages. J Lab Clin Med (1979) 1.20
Sequence variation in the gene for the immunogenic capsid protein VP1 of foot-and-mouth disease virus type A. Proc Natl Acad Sci U S A (1985) 1.19
Laryngeal modeling: theoretical, in vitro, in vivo. Laryngoscope (1987) 1.13
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
Studies on the pathogenesis of fever. XVII. The cationic control of pyrogen release from exudate granulocytes in vitro. J Exp Med (1970) 1.07
Simultaneous isolation of Trichomonas vaginalis and collection of vaginal exudate. Br J Vener Dis (1969) 1.06
Genetic variability among group A and B respiratory syncytial viruses in Mozambique: identification of a new cluster of group B isolates. J Gen Virol (2001) 1.06
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
Solitary eosinophilic granuloma of the lateral orbital wall. Am J Ophthalmol (1985) 1.03
Foot-and-mouth disease virus: immunogenicity and structure of fragments derived from capsid protein VP and of virus containing cleaved VP. Vet Microbiol (1982) 1.01
Dynamics of glucose production and uptake are more closely related to insulin in hindlimb lymph than in thoracic duct lymph. Diabetes (1994) 1.00
Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines. Am J Vet Res (1990) 0.99
Peliosis hepatis in the acquired immunodeficiency syndrome. Arch Pathol Lab Med (1986) 0.99
African swine fever virus multigene family 360 and 530 genes are novel macrophage host range determinants. J Virol (2001) 0.99
Identification of an exposed region of the immunogenic capsid polypeptide VP1 on foot-and-mouth disease virus. J Virol (1983) 0.99
High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology (2001) 0.97
Synovial sarcoma of the head and neck. Arch Otolaryngol Head Neck Surg (1987) 0.96
In vivo analysis of the stability and fitness of variants recovered from foot-and-mouth disease virus quasispecies. J Gen Virol (1998) 0.96
The continuous spread of West Nile virus (WNV): seroprevalence in asymptomatic horses. Epidemiol Infect (2009) 0.96
Videostroboscopy of the canine larynx: the effects of asymmetric laryngeal tension. Laryngoscope (1987) 0.96
Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications. Nephrol Dial Transplant (1997) 0.96
Comparison of vaccine strains and the virus causing the 1986 foot-and-mouth disease outbreak in Spain: epizootiological analysis. Virus Res (1990) 0.95
Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res (1989) 0.90
Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission. J Med Virol (1998) 0.89
Neutralization of foot-and-mouth disease virus. I. Sensitization of the 140S virion by antibody also reactive with the 12S protein subunit. J Gen Virol (1981) 0.88
The effect of recurrent laryngeal nerve stimulation on phonation in an in vivo canine model. Laryngoscope (1989) 0.88
Phenotypic and functional characterization of mouse attenuated and virulent variants of foot-and-mouth disease virus type O1 Campos. Virology (1993) 0.87
Identification of synchronous esophageal tumors in patients with head and neck cancer. J Surg Oncol (1988) 0.86
Effects of supine and lateral positions on cardiac output and intracardiac pressures. Am J Cardiol (1988) 0.86
Effect of trypsin and chymotrypsin on the polypeptides of large and small plaque variants of foot-and-mouth disease virus: relationship to specific antigenicity and infectivity. J Gen Virol (1978) 0.86
Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. J Hepatol (1999) 0.86
Purification and immunogenicity of fusion VP1 protein of foot and mouth disease virus. Biochemistry (1984) 0.84
Effect of superior laryngeal nerve stimulation on phonation in an in vivo canine model. Am J Otolaryngol (1989) 0.84
Radioimmunoassay for detection of VP1 specific neutralizing antibodies of foot and mouth disease virus. J Virol Methods (1985) 0.83
Collaborative social and medical service application. Medinfo (1995) 0.83
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV. J Acquir Immune Defic Syndr (2000) 0.82
Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. J Clin Microbiol (1999) 0.82
Down-regulated lymphoproliferation coincides with parasite maturation and with the collapse of both gamma interferon and interleukin-4 responses in a bovine model of onchocerciasis. Infect Immun (2001) 0.81
Antibodies elicited by a biosynthetic peptide related to a major immunogenic area of FMDV A12. Viral Immunol (1990) 0.80
Use of pulmonary capillary wedge pressure to assess severity of mitral stenosis: is true left atrial pressure needed in this condition? J Am Coll Cardiol (1989) 0.80
A proposed architecture for ambulatory systems development. Medinfo (1995) 0.80
Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE). Vaccine (2013) 0.80
Neutralization of foot-and-mouth disease virus. II. Further parameters related to the sensitization of the 140S virion by antibody. J Gen Virol (1982) 0.79
Effect of supine posture on respiratory mechanics in chronic left ventricular failure. Am J Respir Crit Care Med (2000) 0.79
Effects of canavanine treatment on herpesvirus morphogenesis in cultured cells. Intervirology (1981) 0.78
Nucleotide sequence of the P1 region of serotype Asia1 foot-and-mouth disease virus. Virus Genes (1994) 0.78
Genetic evolution of hepatitis G virus in chronically infected individual patients. J Gen Virol (1998) 0.78
Characterization of three antigenic particles of swine vesicular disease virus. J Gen Virol (1977) 0.78
Pathogenesis of swine vesicular disease in pigs. Am J Vet Res (1979) 0.78
An experimental subunit vaccine for foot-and-mouth disease. Dev Biol Stand (1976) 0.78
Detection of foot-and-mouth disease virus by competitive ELISA using a monoclonal antibody specific for the 12S protein subunit from six of the seven serotypes. Vet Immunol Immunopathol (1990) 0.77
Aneurysm of the brachiocephalic artery in a capuchin monkey (Cebus apella). Lab Anim Sci (1982) 0.77
Failure of acute hyperinsulinemia to alter blood pressure is not due to baroreceptor feedback. Am J Hypertens (1999) 0.77
Purification of foot-and-mouth disease virus infection-associated antigen. Proc Annu Meet U S Anim Health Assoc (1978) 0.77
Imidazole based non-peptide angiotensin II receptor antagonists. Investigation of the effect of the orientation of the imidazole ring on biological activity. Arzneimittelforschung (1993) 0.76
Studies on the pathogenesis of fever. XX. Suppression and regeneration of pyrogen-producing capacity of exudate granulocytes. J Exp Med (1970) 0.76
Experimental swine vesicular disease, pathology and immunofluorescence studies. Can J Comp Med (1979) 0.75
Cross-reactive idiotopes among anti-foot and mouth disease virus neutralizing antibodies. Immunology (1993) 0.75
The family physician and adolescent homosexuality. Am Fam Physician (1994) 0.75
Revolution in practice management: a new kind of drudgery. Arch Fam Med (1993) 0.75
Collaborative Social and Medical Service System. Proc Annu Symp Comput Appl Med Care (1994) 0.75
Corporal punishment. Arch Fam Med (1993) 0.75
Occult primary tumors. The management of isolated submandibular lymph node metastases. Arch Otolaryngol Head Neck Surg (1990) 0.75
Angiotensin receptors in cultured bovine carotid artery smooth muscle cells: comparison with receptors in other smooth muscle cells/tissues. Proc West Pharmacol Soc (1991) 0.75
Early vocal cord carcinoma in obese patients: a surgical lesion. Laryngoscope (1987) 0.75
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure. Antiviral Res (2000) 0.75
A geriatric survey. Health Visit (1973) 0.75
Oral health after periodontal therapy. J Can Dent Assoc (1980) 0.75
Preservation of the electrical-evoked vestibuloocular reflex and otolith-ocular reflex in two patients with markedly impaired canal-ocular reflexes. Ann N Y Acad Sci (1992) 0.75
Bromocriptine in the treatment of secondary amenorrhoea and ovarian dysfunction in hyper- and normo-prolactinaemic patients. Curr Med Res Opin (1978) 0.75
Association between gestational and environmental events and central nervous system function in 7-year-old children. Pediatrics (1975) 0.75
Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattle. Am J Vet Res (1985) 0.75
Technical note: mineral deposits on Dacron bags during ruminal incubation. J Anim Sci (1992) 0.75
Physiotherapy in a hospital based home care programme. Prog Phys Ther (1970) 0.75
How much does the public know about preventive dental health? Dent J (1974) 0.75
African swine fever virus: purification of capsomeres released by lipase. Virology (1990) 0.75
Staff attitudes to an ultrasound-guided peripheral nerve block room for orthopaedic patients. Ir Med J (2014) 0.75
Patient knowledge and attitudes after periodontal therapy. J Can Dent Assoc (1980) 0.75
Transtracheal stimulation of the recurrent laryngeal nerve. Am J Otolaryngol (1988) 0.75
Differentiating cervical lipomas from thyroid nodules. JAMA (1985) 0.75
Serum-prolactin in female infertility. Lancet (1978) 0.75
Human mammary epithelial cells in primary culture reflect c-myc and c-erbB-2 gene copy number in tissue. In Vitro Cell Dev Biol (1992) 0.75
Response of pigs to recent isolates of coxsackievirus B5. Comp Immunol Microbiol Infect Dis (1979) 0.75